A
Arthur I. Sagalowsky
Researcher at University of Texas Southwestern Medical Center
Publications - 50
Citations - 3118
Arthur I. Sagalowsky is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Bladder cancer & Cystectomy. The author has an hindex of 27, co-authored 50 publications receiving 2784 citations. Previous affiliations of Arthur I. Sagalowsky include University of Texas at Austin & University of Texas at Dallas.
Papers
More filters
Journal ArticleDOI
BAP1 loss defines a new class of renal cell carcinoma
Samuel Peña-Llopis,Silvia Vega-Rubin-de-Celis,Silvia Vega-Rubin-de-Celis,Arnold Liao,Nan Leng,Andrea Pavia-Jimenez,Andrea Pavia-Jimenez,Shanshan Wang,Shanshan Wang,Toshinari Yamasaki,Toshinari Yamasaki,Leah Zhrebker,Leah Zhrebker,Sharanya Sivanand,Sharanya Sivanand,Patrick Spence,Patrick Spence,Lisa N. Kinch,Tina Hambuch,Suneer Jain,Yair Lotan,Vitaly Margulis,Arthur I. Sagalowsky,Pia Banerji Summerour,Wareef Kabbani,S. W Wendy Wong,Nick V. Grishin,Marc Laurent,Xian Jin Xie,Christian D. Haudenschild,Mark T. Ross,David R. Bentley,Payal Kapur,James Brugarolas +33 more
TL;DR: The results establish the foundation for an integrated pathological and molecular genetic classification of RCC, paving the way for subtype-specific treatments exploiting genetic vulnerabilities.
Journal ArticleDOI
Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease
Sandra L. Dabora,David Neal Franz,Stephen Ashwal,Arthur I. Sagalowsky,Francis J. DiMario,Daniel K. Miles,Drew Cutler,Darcy A. Krueger,Raul N. Uppot,Rahmin A. Rabenou,S. Camposano,Jan L. Paolini,Fiona M. Fennessy,Nancy Lee,Chelsey Woodrum,Judith Manola,Judy Garber,Elizabeth A. Thiele +17 more
TL;DR: A correlative biomarker study showed that serum VEGF-D levels are elevated at baseline, decrease with sirolimus treatment, and correlate with kidney angiomyolipoma size, which may be a useful biomarker for monitoring kidney angiofibromas.
Journal ArticleDOI
A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma
Sharanya Sivanand,Samuel Peña-Llopis,Hong Zhao,Blanka Kucejova,Patrick Spence,Andrea Pavia-Jimenez,Toshinari Yamasaki,David J. McBride,Jessica Gillen,Nicholas C. Wolff,Lorraine Morlock,Yair Lotan,Ganesh V. Raj,Arthur I. Sagalowsky,Vitaly Margulis,Jeffrey A. Cadeddu,Mark T. Ross,David R. Bentley,Wareef Kabbani,Xian Jin Xie,Payal Kapur,Noelle S. Williams,James Brugarolas +22 more
TL;DR: The development and validation of a tumorgraft model of renal cell carcinoma (RCC) is described and validated and should be useful for testing other targeted drugs preclinically, given that most anticancer drugs that enter clinical trials fail to gain approval.
Journal ArticleDOI
The Impact of Targeted Molecular Therapies on the Level of Renal Cell Carcinoma Vena Caval Tumor Thrombus
Nicholas G. Cost,Scott E. Delacroix,Joshua Sleeper,Paul J. Smith,Ramy F. Youssef,Brian F. Chapin,Jose A. Karam,Stephen H. Culp,E. Jason Abel,James Brugarolas,Ganesh V. Raj,Arthur I. Sagalowsky,Christopher G. Wood,Vitaly Margulis +13 more
TL;DR: This series lacks sufficient statistical power to assess the usefulness of TMTs adequately in tumor thrombus cytoreduction, and it may not be appropriate to extrapolate the experience to all patients with locally advanced RCC.
Journal ArticleDOI
International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy
Shahrokh F. Shariat,Robert S. Svatek,Derya Tilki,Eila C. Skinner,Pierre I. Karakiewicz,Umberto Capitanio,Umberto Capitanio,Patrick J. Bastian,Patrick J. Bastian,Bjoern G. Volkmer,Wassim Kassouf,Giacomo Novara,Hans-Martin Fritsche,Jonathan I. Izawa,Vincenzo Ficarra,Seth P. Lerner,Arthur I. Sagalowsky,Mark P. Schoenberg,Ashish M. Kamat,Colin P.N. Dinney,Yair Lotan,Michael Marberger,Yves Fradet +22 more
TL;DR: In this article, the prognostic value of lymphovascular invasion (LVI) in a large international cohort of patients treated with radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB) was externally validated.